GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis
Otolaryngology–Head and Neck Surgery · 2026
DOI: 10.1002/ohn.70327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2026. Verfasst von Ronit E Malka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Laryngostenosis, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
Objective
Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been associated with systemic anti‐inflammatory effects in addition to weight loss. Their effect on idiopathic subglottic stenosis (iSGS) has not been evaluated. This study aimed to characterize the effect of GLP‐1RAs on surgery‐free interval (SFI) in iSGS. Study Design Retrospective cohort study.
Setting
Single‐institution academic center.
Methods
Two hundred and twenty‐three iSGS patients were reviewed for GLP‐1RA usage. SFI, and secondary measures of weight loss, body mass index (BMI), and Cotton‐Myer grade before and after starting GLP‐1RAs were analyzed. Patients were excluded if GLP‐1RAs were begun prior to establishing SFI, or if serial intralesional steroid injection or endoscopic or open cricotracheal resection were performed. Statistical comparisons for SFI and weight loss were performed with paired t tests, univariate, and multiple linear regression, and a generalized linear mixed‐effects model was used to compare Cotton‐Myer grades, with a threshold for significance of α = .05.
Results
Thirty‐two patients (14%) were taking GLP‐1RAs, with 14 meeting the inclusion criteria. SFI increased by a mean of 10.7 months, or 68.5% ( P = .001). Patients lost 39 pounds on average, with a mean BMI decrement of 6.8 points ( P < .001). There was no appreciable correlation between weight loss, initial BMI, and SFI on multiple linear regression ( P = .92, adjusted R 2 = −0.16) or univariate linear regression between SFI and weight loss ( P = .98, R 2 < 0.001) or BMI ( P = .72, R 2 = 0.01). There was no difference in Cotton‐Myer grade at the time of surgery between patients before and after starting therapy ( P = .44).
Conclusion
GLP‐1RA therapy increases SFI in iSGS independent of initial BMI or weight loss. Level of Evidence IV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.
ORCID-Profile: Ronit E Malka, Vasiliki Triantafillou, Niloufar Saeedi, Lee M Akst, Kevin Motz, Alexander T Hillel
Zitieren
APA
Malka, R. E., Collins, S., Triantafillou, V., Saeedi, N., Akst, L. M., Best, S. R., Motz, K., & Hillel, A. T. (2026). GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70327
Vancouver
Malka RE, Collins S, Triantafillou V, Saeedi N, Akst LM, Best SR, et al. GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70327
BibTeX
@article{Malka2026,
author = {Malka, Ronit E and Collins, Sam and Triantafillou, Vasiliki and Saeedi, Niloufar and Akst, Lee M and Best, Simon R and Motz, Kevin and Hillel, Alexander T},
title = {GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
doi = {10.1002/ohn.70327}
}
EUVIMED